The MEA electrophysiology market is expected to grow from US$ 359.62 million in 2022 to US$ 595.45 million by 2028; it is estimated to grow at a CAGR of 8.8% from 2022 to 2028.
Emerging markets are expected to offer significant growth opportunities to electrophysiology market players due to their growing patient population, increasing adoption of cardiogram systems, growing awareness of cardiovascular diseases, rising disposable incomes, improving healthcare infrastructure, and comparatively lenient policies compared to developed countries across the region. Emerging markets have seen a sustained increase in the number of surgical procedures over the past decade, driven by the growing target population of patients, rising cardiovascular disease-related deaths, and increasing medical tourism. Manufacturers are strategically focusing on expanding their presence in developing MEA countries to capitalize on the high growth opportunities for electrophysiology devices in emerging markets. Thus, increasing competition in well-established markets will force electrophysiology device manufacturers to focus on emerging markets in the coming years.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the MEA electrophysiology market at a substantial CAGR during the forecast period.
MEA Electrophysiology Market Revenue and Forecast to 2028 (US$ Million)
MEA Electrophysiology Market Segmentation
The MEA electrophysiology market is segmented based on product, indication, and country. Based on product, the market is segmented into electrophysiology ablation catheters, electrophysiology laboratory devices, electrophysiology diagnostic catheters, access devices, and others. The electrophysiology laboratory devices segment dominated the market in 2022 and electrophysiology ablation catheters segment is expected to be fastest growing during forecast period. Based on indication, the market is segmented into atrial fibrillation (AF), atrial flutter, atrioventricular nodal reentry tachycardia (AVNRT), wolff-parkinson-white syndrome (WPW), and others. The atrial fibrillation (AF) segment dominated the market in 2022 and is expected to be fastest growing during forecast period. Based on country, the MEA electrophysiology market is segmented into South Africa, Saudi Arabia, the UAE, and the Rest of MEA.
Abbott; Biotronik, Inc.; Boston Scientific Corporation; CardioFocus; GE Healthcare; Johnson & Johnson Services, Inc.; Koninklijke Philips N.V.; Medtronic; MicroPort Scientific Corporation; and Siemens Healthineers AG are among the leading companies operating in the MEA electrophysiology market.